Suven Pharmaceuticals acquires 56% stake in NJ Bio

21 Dec 2024 Evaluate

Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc., at an aggregate consideration of $64.4 million, which includes $15 million of primary equity infusion into the NJ Bio. Therefore, the acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024.

Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.


Suven Pharma Share Price

1157.55 -51.20 (-4.24%)
27-Feb-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1647.60
Dr. Reddys Lab 1125.90
Cipla 1441.15
Lupin 1891.45
Zydus Lifesciences 886.50
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on